CollPlant Biotechnologies (CollPlant Biotechnologies) Forward Dividend Yield % : 0.00% (As of Jun. 07, 2024)

View and export this data going back to 2021. Start your Free Trial

What is CollPlant Biotechnologies Forward Dividend Yield %?

As of today (2024-06-07), the Forward Annual Dividend Yield of CollPlant Biotechnologies is 0.00%.

As of today (2024-06-07), the Trailing Annual Dividend Yield of CollPlant Biotechnologies is 0.00%.

CLGN's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.63
* Ranked among companies with meaningful Forward Dividend Yield % only.

CollPlant Biotechnologies's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of CollPlant Biotechnologies's Forward Dividend Yield %

For the Biotechnology subindustry, CollPlant Biotechnologies's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CollPlant Biotechnologies's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's Forward Dividend Yield % falls into.

CollPlant Biotechnologies Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

CollPlant Biotechnologies (NAS:CLGN) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

CollPlant Biotechnologies Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

CollPlant Biotechnologies (CollPlant Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (NAS:CLGN) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

CPT:Germany

Address

4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104

Website

https://www.collplant.com

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The company's revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing.